| 0.0322 0 (0%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
TRACON Pharmaceuticals, Inc. functions as a biopharmaceutical enterprise, primarily dedicated to the discovery, development, and eventual market launch of cancer treatments within the United States. Its current product pipeline features several assets in various stages of clinical trials. These include envafolimab (KN035), a PD-L1 single-domain antibody being investigated for the treatment of soft tissue sarcoma, and YH001, an experimental humanized CTLA-4 IgG1 monoclonal antibody targeting a range of cancer indications. Further clinical-stage compounds are TRC102, a small molecule undergoing Phase II evaluation for mesothelioma, and Phase I studies for solid tumors, lymphomas, lung cancer, and glioblastoma. Additionally, TJ004309, a CD73 antibody, is in Phase I clinical development for solid tumors. To bolster its development efforts, TRACON has forged a series of collaboration and licensing agreements. These encompass partnerships with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for envafolimab; I-Mab Biopharma for the CD73 antibody TJ004309; and Case Western Reserve University for TRC102. The company also maintains a cooperative research and development agreement with the National Cancer Institute. Established in 2004, the firm was initially known as Lexington Pharmaceuticals, Inc. before officially changing its name to TRACON Pharmaceuticals, Inc. in March 2005. Its corporate headquarters are located in San Diego, California.
Fri, 11 Sep 2026
TRACON Pharmaceuticals Inc (NASDAQ: TCON) Share Price, TCON Stock News, TCON Share Price & Updates - Kalkine
Tue, 30 Jul 2024
TRACON Pharmaceuticals Announces it Will Wind Down Operations - globenewswire.com
Tue, 05 Mar 2024
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End - globenewswire.com
Tue, 21 Nov 2023
Tracon Pharma (NASDAQ: TCON) up 58% - it might, actually, have something to sell - dhakatribune.com
Mon, 20 Nov 2023
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment - globenewswire.com
Sat, 09 Sep 2023
TCON ETF Price and Chart — TSX:TCON - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|